Imetelstat Displays Early Efficacy in Myelofibrosis; Phase 3 Trial Is Underway

The first-in-class telomerase inhibitor imetelstat is poised to expand the myelofibrosis treatment armamentarium should it prove safe and effective in the newly initiated phase 3 IMpactMF trial.

Related Keywords

New York ,United States ,Johno Mascarenhas , ,Icahn School Of Medicine At Mount Sinai ,Blood Cancers ,Myeloid Disorders ,Icahn School ,Mount Sinai ,Myelofibrosis Symptom Assessment Form ,Patients With Myelofibrosis ,Imetelstat ,Impactmf Trial ,Nct04576156 ,D ,Imbark Trial ,Nct02426086 ,